UY34201A - Compuestos de azaindol y métodos para el tratamiento de vih. - Google Patents

Compuestos de azaindol y métodos para el tratamiento de vih.

Info

Publication number
UY34201A
UY34201A UY0001034201A UY34201A UY34201A UY 34201 A UY34201 A UY 34201A UY 0001034201 A UY0001034201 A UY 0001034201A UY 34201 A UY34201 A UY 34201A UY 34201 A UY34201 A UY 34201A
Authority
UY
Uruguay
Prior art keywords
azaindol
compounds
methods
hiv treatment
hiv
Prior art date
Application number
UY0001034201A
Other languages
English (en)
Inventor
Martha Alicia De La Rosa
Brian Alvin Johns
Emile Johann Velthuisen
Weatherhead Jason
Samano Vicente
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of UY34201A publication Critical patent/UY34201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos y sales farmacéuticamente aceptables de los mismos, sus composiciones farmacéuticas, sus métodos de preparación, y su uso para el tratamiento de infecciones virales mediadas por un miembro de la familia de retrovirus, tal como el virus de inmunodeficiencia humana (HIV).
UY0001034201A 2011-07-15 2012-07-13 Compuestos de azaindol y métodos para el tratamiento de vih. UY34201A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161508197P 2011-07-15 2011-07-15

Publications (1)

Publication Number Publication Date
UY34201A true UY34201A (es) 2013-02-28

Family

ID=47519251

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034201A UY34201A (es) 2011-07-15 2012-07-13 Compuestos de azaindol y métodos para el tratamiento de vih.

Country Status (8)

Country Link
US (1) US8609653B2 (es)
EP (1) EP2731436B1 (es)
JP (1) JP6055468B2 (es)
AR (1) AR087184A1 (es)
ES (1) ES2624984T3 (es)
TW (1) TW201317237A (es)
UY (1) UY34201A (es)
WO (1) WO2013012649A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640729B1 (en) 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibitors of hiv replication
EP2781519B1 (en) * 2011-11-15 2019-10-30 ST Pharm Co., Ltd. Novel antiviral pyrrolopyridine derivative and a production method for same
PT2877468T (pt) 2012-07-12 2017-11-21 Viiv Healthcare Uk Ltd Compostos e métodos para o tratamento de vih
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
PT3105236T (pt) 2014-02-12 2017-12-22 Viiv Healthcare Uk (No 5) Ltd Macrociclos de benzotiazole como inibidores da replicação do vírus da imunodeficiência humana
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
EP3116879A1 (en) 2014-02-18 2017-01-18 VIIV Healthcare UK (No.5) Limited Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9834566B2 (en) 2014-02-18 2017-12-05 VIIV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
CN103864661A (zh) * 2014-04-01 2014-06-18 湖南华腾制药有限公司 一种2-氨基-3-氰基吡咯衍生物的合成工艺
EP3144311A4 (en) 2014-05-16 2018-01-03 Shionogi & Co., Ltd. Tricyclic heterocyclic derivative having hiv replication-inhibiting effect
KR101592370B1 (ko) * 2014-06-09 2016-02-11 한국화학연구원 신규한 피롤로피리딘 유도체 및 이의 hiv 저해제로서의 용도
US10112899B2 (en) * 2014-07-08 2018-10-30 Viiv Healthcare Uk Limited Isoindoline derivatives for use in the treatment of a viral infection
PT3172200T (pt) 2014-07-22 2019-01-17 Viiv Healthcare Uk Ltd Derivados de isoindolinona úteis como agentes antivirais
JP6614585B2 (ja) 2015-05-29 2019-12-04 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する含窒素３環性誘導体
JP2018520162A (ja) * 2015-07-06 2018-07-26 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
KR20180025926A (ko) * 2015-07-08 2018-03-09 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서의 피리딘-3-일 아세트산 유도체
JP6898914B2 (ja) 2015-07-20 2021-07-07 ジェンザイム・コーポレーション コロニー刺激因子−１受容体（ｃｓｆ−１ｒ）阻害剤
WO2018020357A1 (en) 2016-07-25 2018-02-01 Viiv Healthcare Uk Limited Indoline derivatives
MX2019011220A (es) * 2017-03-24 2019-11-01 St Pharm Co Ltd Compuesto de pirrolopiridina novedoso, metodo de preparacion del mismo y uso del mismo.
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
KR20220023187A (ko) * 2020-08-20 2022-03-02 에스티팜 주식회사 피롤로피리딘 유도체 및 이들의 용도
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
US20240317737A1 (en) * 2021-01-11 2024-09-26 St Pharm Co., Ltd. Pyrrolopyridine derivative preparation method
CN113173884B (zh) * 2021-05-06 2023-08-15 陕西师范大学 二氯二茂钛催化汉斯酯1,4-二氢吡啶类化合物合成吡啶及其衍生物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1196384A4 (en) * 1999-06-25 2002-10-23 Merck & Co Inc 1- (AROMATIC OR HETEROAROMATICALLY SUBSTITUTED) -3- (HETEROAROMATICALLY SUBSTITUTED) -1,3-PROPANDIONS AND THEIR APPLICATIONS
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PL364469A1 (en) 2001-03-19 2004-12-13 Ono Pharmaceutical Co, Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
US7605168B2 (en) * 2004-09-03 2009-10-20 Plexxikon, Inc. PDE4B inhibitors
EP2220095B1 (en) * 2007-11-15 2013-01-02 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2220084B1 (en) * 2007-11-16 2014-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US9132129B2 (en) * 2010-11-15 2015-09-15 Katholieke Universiteit Leuven Antiviral compounds

Also Published As

Publication number Publication date
US8609653B2 (en) 2013-12-17
EP2731436A1 (en) 2014-05-21
WO2013012649A1 (en) 2013-01-24
ES2624984T3 (es) 2017-07-18
TW201317237A (zh) 2013-05-01
JP2014522858A (ja) 2014-09-08
AR087184A1 (es) 2014-02-26
JP6055468B2 (ja) 2016-12-27
US20130018049A1 (en) 2013-01-17
EP2731436B1 (en) 2017-03-08
EP2731436A4 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34648A (es) Amidas como inhibidores de pim
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY34550A (es) Bencilpirazoles sustituidos
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
UY34559A (es) Inhibidores de bromodominios
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34820A (es) Compuestos tipo pirrolo-pirrolidinona
UY34503A (es) ?sal de bromhidrato de pridopidina?
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34146A (es) Compuestos inhibidores de metaloenzimas
UY34817A (es) Tienopirimidinas
UY34374A (es) Benzilindazoles sustituidos
UY34401A (es) Métodos para el tratamiento de hcv
UY34402A (es) Métodos para el tratamiento de hcv
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
UY34824A (es) Nucleósidos de espirooxetano de uracilo

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020